SynthesisLasers in medical science2025
Toward noninvasive precision: a meta-analysis of photoacoustic spectroscopy in breast cancer.
Synthesis in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most common lethal cancers in the world. Standard diagnostic methods, particularly tissue biopsies, are invasive and often fail to detect tumor heterogeneity, leading to suboptimal treatment outcomes. This study aims to assess and evaluate the potential of photoacoustic imaging (PAI) and photoacoustic spectroscopy (PAS) as noninvasive technologies that replace conventional methods for diagnosing breast cancer with increased depth of tissue penetration, improved resolution, and molecular sensitivity. This meta-analysis introduces the principal advantages and limitations of the PAI and PAS technologies. It applies a statistical approach to assess diagnostic performance, sensitivity, and specificity in preclinical and experimental settings. Data from six relevant studies on PAS for breast cancer screening were summarized. The analysis revealed a pooled sensitivity of 84% and specificity of 96% to assess the diagnostic performance of the PAS/PAI technologies. The estimate of pooled logit-transformed diagnostic performance was 0.72 (95% CI: 0.71-0.72), equivalent to 84% pooled sensitivity and 96% specificity. The logit value reflects variance-stabilized analysis and cannot be interpreted as uncorrected diagnostic accuracy, and the average heterogeneity across studies was moderate (I
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.